Skip to main content
TipRanks
Go Ultimate75% OFF

Medivir AB (0GP7) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Medivir AB has a market cap or net worth of SEK 680.36M. The enterprise value is SEK 778.76M.

Market Cap
SEK 680.36M
Enterprise Value
SEK 778.76M

Share Statistics

Medivir AB has 624,179,440 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
624,179,440
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Medivir AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

Return on Equity (ROE)
―
Return on Assets (ROA)
―
Return on Invested Capital (ROIC)
―
Return on Capital Employed (ROCE)
―
Revenue Per Employee
―
Profits Per Employee
40.41M
Employee Count
7
Asset Turnover
―
Inventory Turnover
―

Income Statement

In the last 12 months, Medivir AB had revenue of ― and earned 282.85M in profits. Earnings per share was ―.

Revenue
―
Gross Profit
77.09M
Operating Income
-312.38M
Pretax Income
―
Net Income
282.85M
EBITDA
-270.87M
Earnings Per Share (EPS)
―

Dividends & Yields

Medivir AB pays an annual dividend of SEK 0.29, resulting in a dividend yield of ―

Dividend Per Share
SEK 0.29
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
―
Earnings Yield
―

Stock Price Statistics

Beta
1.35
52-Week Price Change
94.91%
50-Day Moving Average
1.56
200-Day Moving Average
1.79
Relative Strength Index (RSI)
1.70
Average Volume (3m)
19.30K

Important Dates

Medivir AB upcoming earnings date is Feb 18, 2027, Before Open (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 18, 2027
Ex-Dividend Date
Mar 15, 2022

Balance Sheet

Medivir AB has ― in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of ― billion.

Cash & Marketable Securities
―
Total Debt
SEK 0.00
Net Cash
―
Net Cash Per Share
―
Tangible Book Value Per Share
―

Analyst Forecast

The average price target for Medivir AB is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
110.00%
EPS Growth Forecast
60.96%